One Year After Go-Live, NOVO Hospital Confirms the Long-Term Value of Digital Pathology with Tribun Health
PARIS, FRANCE / ACCESS Newswire / December 16, 2025 / One year after deploying CaloPix®, the digital pathology platform developed...
Month: December 2025
One Year After Go-Live, NOVO Hospital Confirms the Long-Term Value of Digital Pathology with Tribun Health
PARIS, FRANCE / ACCESS Newswire / December 16, 2025 / One year after deploying CaloPix®, the digital pathology platform developed...
Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy
A Look Back at Key Milestones and Successes Achieved in 2025What's Ahead: Exciting Plans, Strategic Outlook, and Goals for 2026Advancing...
Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy
A Look Back at Key Milestones and Successes Achieved in 2025What's Ahead: Exciting Plans, Strategic Outlook, and Goals for 2026Advancing...
Join AIML’s Live Shareholder Update with Chairman & CEO Paul Duffy
A Look Back at Key Milestones and Successes Achieved in 2025What's Ahead: Exciting Plans, Strategic Outlook, and Goals for 2026Advancing...
How to Choose the Best Plastic Surgeon in Tampa, FL: Gruber Plastic Surgery Releases Patient Safety Checklist
New Tampa resource explains what to verify before booking a consult-board certification, facility standards, anesthesia planning, and how to assess...
How to Choose the Best Plastic Surgeon in Tampa, FL: Gruber Plastic Surgery Releases Patient Safety Checklist
New Tampa resource explains what to verify before booking a consult-board certification, facility standards, anesthesia planning, and how to assess...
How to Choose the Best Plastic Surgeon in Tampa, FL: Gruber Plastic Surgery Releases Patient Safety Checklist
New Tampa resource explains what to verify before booking a consult-board certification, facility standards, anesthesia planning, and how to assess...
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members...
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members...
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members...
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep SolutionsLITTLETON, Colo., Dec. 16,...
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep SolutionsLITTLETON, Colo., Dec. 16,...
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep SolutionsLITTLETON, Colo., Dec. 16,...
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Vancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...